The Treatment Stopped—Did the Benefit Last? New Baricitinib Data in Type 1 Diabetes

New follow-up research on baricitinib for type 1 diabetes addresses a crucial question: what happens after the drug is stopped? The original BANDIT trial showed that 48 weeks of oral baricitinib helped preserve beta-cell function in people with recently diagnosed type 1 diabetes. However, new follow-up research examines participants through week 96, providing a clearer picture of whether those benefits continue without treatment. The findings suggest that early immune intervention can protect remaining insulin-producing cells, but the protection may not be permanent once therapy ends.

Table of Contents

• What the original BANDIT trial found
• What happened after baricitinib was stopped
• Why the durability findings matter
• Where baricitinib may fit in future type 1 diabetes care
• Conclusion
• FAQs

Why Baricitinib Research in Type 1 Diabetes Matters

Type 1 diabetes is driven by an autoimmune attack on pancreatic beta cells, which make insulin. Therefore, researchers have increasingly looked beyond replacing insulin and toward therapies that may slow the immune process itself. Baricitinib, marketed as Olumiant for approved indications outside type 1 diabetes, is an oral Janus kinase, or JAK, inhibitor. By blocking JAK1 and JAK2 signaling, the drug can interfere with inflammatory pathways involved in immune activity.

The phase 2 BANDIT trial tested this approach in 91 participants ages 10 to 30 who had been diagnosed with type 1 diabetes within the previous 100 days. Participants received either baricitinib 4 mg daily or placebo for 48 weeks. At week 48, stimulated C-peptide, an important marker of the body’s remaining insulin production, was higher in the baricitinib group. In addition, participants taking the drug required less daily insulin and had lower glucose variability. HbA1c, however, was similar between the groups. These findings were reported in The New England Journal of Medicine.

Those findings raised an important possibility. Perhaps early immune treatment could preserve beta cells during a critical window after diagnosis. Yet another question remained: would that protection continue after treatment stopped?

What Happened One Year After Baricitinib Stopped?

The follow-up provides an answer, although it is more complicated than researchers might have hoped. Of the original 91 randomized participants, 88 completed the week 96 follow-up. Investigators assessed C-peptide responses, HbA1c, insulin doses, continuous glucose monitoring measures, immune-cell characteristics, and other outcomes.

At week 72, which was 24 weeks after treatment ended, mean C-peptide remained significantly higher among participants previously assigned to baricitinib. However, by week 96, the difference was no longer statistically significant. Mean C-peptide was 0.43 in the baricitinib group compared with 0.35 nmol/L in the placebo group, with a P value of 0.336. Researchers also found no significant differences between groups in insulin dose, HbA1c, or CGM measures during the post-treatment follow-up. The complete follow-up findings are available in Diabetes Care.

In other words, the benefit of baricitinib in type 1 diabetes did not simply remain unchanged after treatment was discontinued. Instead, the advantage gradually faded during the following 48 weeks.

Immune findings pointed in the same direction. Changes in effector memory CD8-positive T cells seen during treatment had resolved by week 96. Consequently, the researchers concluded that the therapeutic benefits waned after baricitinib was stopped and that durable benefit would likely require continued treatment.

Beta-Cell Preservation May Depend on Continued Therapy

These results help clarify an important distinction between suppressing an autoimmune process and permanently resetting it. Baricitinib appeared to protect beta-cell function while participants were receiving treatment. Yet the follow-up suggests that a 48-week course did not create lasting immune tolerance in the overall study population.

Interestingly, researchers also observed a possible age-related difference. In a post hoc analysis, adults who had received baricitinib showed full preservation of beta-cell function when treatment ended at week 48. In contrast, children in the treatment group had already experienced some C-peptide decline relative to baseline. Because this was a post hoc comparison and involved small groups, it should be interpreted cautiously. Still, the finding could help shape future research into age, timing, and treatment response.

The results also reinforce why C-peptide preservation has become a major goal in disease-modifying type 1 diabetes research. Remaining beta-cell function means the body continues producing at least some insulin. Diabetes In Control has previously explored the importance of beta-cell preservation and immunotherapy and how treatment strategies for newly diagnosed type 1 diabetes are evolving. These approaches reflect a broader shift from managing glucose alone toward modifying the underlying disease.

What the Findings Mean for Future Type 1 Diabetes Treatment

The latest findings on baricitinib for type 1 diabetes are not evidence that the therapy failed. Rather, they help define what the treatment appears capable of doing and what may be required to sustain its effects. During active therapy, the original trial showed greater preservation of beta-cell function with baricitinib than with placebo. After treatment stopped, however, that advantage gradually narrowed.

That pattern creates new questions for clinical research. Would longer treatment preserve beta cells for longer? Could retreatment work? Might baricitinib be more effective in selected patients or combined with another immune therapy? Most importantly, can longer treatment deliver a favorable benefit-risk balance?

Those questions matter because baricitinib is an immunomodulatory drug, and long-term therapy requires careful safety evaluation. The original BANDIT trial was relatively small and involved young people with recent-onset disease. Although adverse-event frequency and severity were similar between the treatment and placebo groups during the original 48-week trial, larger and longer studies are needed before broader conclusions can be made.

For now, baricitinib should not be viewed as a replacement for insulin. Instead, the research provides evidence that targeting immune pathways can influence the course of newly diagnosed type 1 diabetes. Patients interested in disease-modifying treatment should discuss available and approved options with an appropriate diabetes specialist.

Conclusion

The latest BANDIT follow-up answers one major question while opening several others. Baricitinib preserved beta-cell function during treatment, and some benefit remained six months after therapy stopped. By one year off treatment, however, the overall C-peptide advantage was no longer statistically significant, while differences in insulin requirements, HbA1c, and CGM outcomes were also absent.

Therefore, the emerging lesson is that baricitinib may control important immune processes rather than permanently switch them off. Future studies will need to determine whether longer or continuous treatment can safely provide durable beta-cell preservation. For clinicians, the findings add another important piece to the rapidly evolving disease-modifying type 1 diabetes landscape.

FAQs

What is baricitinib?

Baricitinib, sold as Olumiant for approved conditions, is an oral JAK inhibitor that blocks immune signaling pathways involved in inflammation. It is being studied as an immune therapy for recently diagnosed type 1 diabetes.

Did baricitinib preserve beta-cell function in type 1 diabetes?

Yes. During the 48-week BANDIT trial, participants receiving baricitinib had significantly greater stimulated C-peptide levels than those receiving placebo, suggesting better preservation of remaining beta-cell function.

Did the benefit continue after baricitinib was stopped?

The benefit persisted initially but weakened over time. C-peptide remained significantly higher at week 72, but the difference between groups was no longer statistically significant at week 96.

Does baricitinib replace insulin for type 1 diabetes?

No. The research evaluates baricitinib as a potential disease-modifying therapy, not as an insulin replacement. People with type 1 diabetes still require appropriate insulin management.

What is the main lesson from the follow-up study?

The findings suggest that preserving beta-cell function with baricitinib may require continued treatment. Larger and longer studies will be needed to determine the safest and most effective treatment strategy.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.